INCY vs LLY
Incyte vs Eli Lilly and Company — AI-powered side-by-side comparison
VS
LLY
Eli Lilly and Company
68
Buy
| Metric | INCY | LLY |
|---|
| AI Score |
73
|
68
|
| Price |
$120.19
|
$1,180.33
|
| P/E Ratio |
14.78×
|
39.54×
|
| ROE |
24.9%
|
77.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
84.0%
|
| Debt / Equity |
0.01×
|
1.62×
|
| Dividend Yield |
0.0%
|
0.6%
|
| RSI (14) |
51.8
|
57.1
|
| Beta |
0.769
|
0.506
|
| Expected Upside |
—
|
+5.8%
|
AI Committee View
Current Innellis committee reasoning for INCY versus LLY.
INCY leads by 5 points.
INCY scores 73/100 (Buy) versus LLY at 68/100 (Buy).
INCY Committee View
100% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
LLY Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth